212 related articles for article (PubMed ID: 18347159)
1. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
Logothetis CJ; Navone NM; Lin SH
Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
3. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
4. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
5. Bone directed therapies for prostate cancer.
Bradley DA; Hussain M; Dipaola RS; Kantoff P
J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
[TBL] [Abstract][Full Text] [Related]
6. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
7. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications.
Chung LW
Cancer; 2003 Feb; 97(3 Suppl):772-8. PubMed ID: 12548574
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
10. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
Loberg RD; Gayed BA; Olson KB; Pienta KJ
J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
[TBL] [Abstract][Full Text] [Related]
11. In vivo models of prostate cancer metastasis to bone.
Singh AS; Figg WD
J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
[TBL] [Abstract][Full Text] [Related]
12. Targeting of therapeutic agents to bone to treat metastatic cancer.
Bagi CM
Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
[TBL] [Abstract][Full Text] [Related]
13. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
14. The role of the stromal microenvironment in prostate cancer.
Condon MS
Semin Cancer Biol; 2005 Apr; 15(2):132-7. PubMed ID: 15652458
[TBL] [Abstract][Full Text] [Related]
15. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
16. Bone and prostate cancer cell interactions in metastatic prostate cancer.
Vela I; Gregory L; Gardiner EM; Clements JA; Nicol DL
BJU Int; 2007 Apr; 99(4):735-42. PubMed ID: 17166237
[TBL] [Abstract][Full Text] [Related]
17. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
18. Bone-directed treatments for prostate cancer.
Saad F
Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
[TBL] [Abstract][Full Text] [Related]
19. When prostate cancer meets bone: control by wnts.
Emami KH; Corey E
Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
[TBL] [Abstract][Full Text] [Related]
20. Gene-modified bone marrow cell therapy for prostate cancer.
Wang H; Thompson TC
Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
